BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » acquisition » Page 2

Merck KGaA Completes Acquisition of Sigma-Aldrich for $17 Billion ($140 per Share)

November 18, 2015 By Cade Hildreth (CEO) Leave a Comment

Merck KGaA Completes Acquisition of Sigma-Aldrich for $17 Billion

Merck KGaA  is best known for being a major player in the pharmaceutical space.  More specifically, the company is a multinational chemical, pharmaceutical and life sciences company headquartered in Darmstadt, Germany, that boasts over 40,000 employees spread across 70+ countries worldwide.

For those of us involved the stem cell world, Sigma-Aldrich is best known as a provider of research products and reagents. The company offers a diverse suite of stem cell specific research products, including a complete line of stem cell products for embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) research, as well as mesenchymal stem cell research, neural stem cell reagents, and more.

However, Sigma-Aldrich is actuallydiversified as well. It is an American multinational chemical, life science, and biotechnology company, headquartered in St. Louis, MO. It has nearly 10,000 employees spread across more than 40 countries worldwide and is an honored member of the Fortune 1000, a list of the 1000 largest American companies, ranked by revenue.

Previously announced in September of 2014, Merck KGaA stated it would acquire Sigma-Aldrich for $17.0 billion. However, the deal required approval from national regulatory agencies within Europe before it could become official. Specifically, the board of directors for Sigma-Aldrich approved an agreement under which Merck KGaA would acquire Sigma-Aldrich for $140.00 per share in cash. At that time, it was unknown when the deal would close, although a mid-2015 timeline was loosely anticipated.

In major news released today, November 18, 2015, Merck KGaA has announced that it has completed its acquisition of Sigma-Aldrich Corporation for $140 per share, a deal valued at $17.0 billion. 

For those unfamiliar with the history of Merck KGaA, EMD Millipore is an American-based subsidiary of its German parent company, Merck KGaA. It is known as Merck Millipore outside the United States and Canada.

Therefore, EMD Millipore and Sigma-Aldrich will now be one organization within Merck KGaA, which will be known as “MilliporeSigma” within the U.S. and Canada.

As the deal is valued at approximately $17 billion, it is a massive acquisition with the life science sector. The completed deal resulted from recent approvals provided by the European Commission, which was the last remaining antitrust condition necessary to allow Sigma-Aldrich to become a fully owned business unit of Merck KGaA. Importantly, Merck KGaA will now offer a diverse portfolio of more than 300,000 products, making it the leading player in a $130 billion global life science industry.

Congratulations to all involved with this massive transaction and here’s to hoping the it will continue to emphasize the development of new and progressive stem cell research products and reagents.

Need detailed market analysis for the stem cell or cord blood industry? View our global strategic reports here.

Filed Under: iPS Cells, MSCs, Neural Stem Cells, Stem Cells Tagged With: acquisition, EMD Millipore, market news, Merck KGaA, Sigma Aldrich, stem cells

Astella Acquires Ocata Therapeutics for $379M

November 13, 2015 By Cade Hildreth (CEO) Leave a Comment

Astellas Acquires Ocata

Astellas Acquires OcataAstellas Pharma announced it is acquiring Ocata Therapeutics for $379M. Headquartered in Tokyo, Japan, Astellas is the second largest drug company in Japan, generating over $10 billion in drug sales last year, while Ocata is headquartered in Marlborough, Massachusetts. Astellas’ cash flow is essential, because the company has agreed to pay $8.50 a share for Ocata, a 79% premium over the stock price last Friday. [Read more…]

Filed Under: iPS Cells, MSCs, Stem Cells Tagged With: acquisition, astellas pharma, cell therapy, hESC, iPSC, Ocata Therapeutics

Consolidation Continues within the Cord Blood Market – AlphaCord Acquires LifeSource Cryobank

November 13, 2015 By Cade Hildreth (CEO) Leave a Comment

Consolidation Continues within the Cord Blood Market - AlphaCord Acquires LifeSource Cryobank

Today, AlphaCord released the major news that it is acquiring LifeSource Cryobank. This merger continues the trend of consolidation within the global cord blood banking market. It also continues AlphaCord’s trend of consolidation, as this was its fifth acquisition of smaller cord blood banks.

Earlier this year, on June 29, 2015, the largest cord blood bank in the United States and the world, Cord Blood Registry® (CBR®) announced that it had entered into a definitive agreement to be acquired by AMAG Pharmaceuticals, a company based out of Based in Waltham, Massachusetts. The value of the deal was set at $700 million, which established value of over 5.55 times revenue and over 15.55 times EBITDA. [Read more…]

Filed Under: Cord Blood, HSCs, MSCs, Press Releases Tagged With: acquisition, AlphaCord, cord blood, market news, press release

5 Types of Cord Blood Market Participants Impacted by AMAG Pharma’s Acquisition of Cord Blood Registry (CBR®)

June 30, 2015 By Cade Hildreth (CEO) Leave a Comment

Cord Blood Registry Acquired by AMAG Pharmaceuticals

On June 29, 2015, AMAG Pharmaceuticals released news that reverberated throughout the cord blood banking industry worldwide, announcing that it had entered into a definitive agreement to acquire Cord Blood Registry (CBR®) for $700 million. The acquisition is expected to close during the third-quarter of 2015, based on regulatory approvals and execution of agreed upon terms and conditions.

Direct Participants in the Cord Blood Deal

Founded in 1992 and headquartered in San Bruno, California, Cord Blood Registry® is the largest cord blood bank in the United States and the world.  CBR® currently stores over 500,000 preserved cord blood and cord tissue units, which is substantially more than its nearest competitor, ViaCord, which has approximately 350,000 units stored.   [Read more…]

Filed Under: Cord Blood, HSCs, Stem Cells Tagged With: acquisition, AMAG Pharmaceuticals, cord blood, Cord Blood Registry

FUJIFILM Acquires Cellular Dynamics International (CDI)

April 2, 2015 By Cade Hildreth (CEO) Leave a Comment

Stem Cell Industry Acquisition between CDI and Fuji Film

CDI / FUJIFILMTOKYO and MADISON, Wis., March 30, 2015 — FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) (“Fujifilm”) and Cellular Dynamics International, Inc. (CEO: Robert Palay) (“CDI”), a leading developer and manufacturer of fully functioning human cells in industrial quantities, announced that the two companies have entered into a agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger. [Read more…]

Filed Under: iPS Cells Tagged With: acquisition, CDI, FUJIFILM, iPSC, market news

  • « Previous Page
  • 1
  • 2

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.